Resverlogix Corp
11 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of Apabetalone in Subjects With Long -COVID (NCT06590324) | Resverlogix Corp | 2025-04-15 |
| A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis (NCT03160430) | Resverlogix Corp | 2024-11-22 |
| Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease (NCT03228940) | Resverlogix Corp | 2022-11-22 |
| An Open-Label Study of Apabetalone in Covid Infection (NCT04894266) | Resverlogix Corp | 2022-01-14 |
Track Resverlogix Corp automatically
Every clearance here is in the API, with alerts when new ones post.